興齊眼藥(300573.SZ):環孢素滴眼液(Ⅱ)獲藥品註冊批件
格隆匯 6 月 22日丨興齊眼藥(300573.SZ)公佈,公司收到國家藥品監督管理局核准簽發的環孢素滴眼液(Ⅱ)《藥品註冊批件》。
環孢素是一種免疫抑制劑。公司獲批的環孢素滴眼液(Ⅱ)可促進乾眼症患者的淚液分泌,適用於與角結膜乾燥症相關的眼部炎症所導致的淚液生成減少的患者。
2002年,美國艾爾健公司的環孢素眼用製劑(Restasis®)在美國上市,該產品是全球首個用於乾眼症的環孢素眼用製劑,已先後在多個國家上市,尚未在中國上市。環孢素滴眼液(Ⅱ)是中國首個獲批上市的用於乾眼症的環孢素眼用製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.